natgillin/translations-raw huggingface dataset:
Children and adolescents This medicine is not recommended for use in children and adolescents under 18 years. 
To zdravilo ni priporočeno za zdravljenje otrok in mladostnikov, mlajših od 18 let.
There is no experience with doses above 600 mg in humans. 
Z odmerki nad 600 mg pri ljudeh ni izkušenj.
Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), or very rare (< 1/10,000) and not known (cannot be estimated from the available data). 
Po pogostnosti so opredeljeni kot zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000) ali zelo redki (< 1/10.000) in neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
Other side effects of Jentadueto include: 
Drugi neželeni učinki zdravila Jentadueto vključujejo:
Oral contraceptives: 
Peroralni kontraceptivi:
HbA1c (%) Number of patients n = 65 n = 135 
HbA1c (%) Število bolnikov n = 65 n = 135
A GFR should be assessed before initiation of treatment with metformin containing products and at least annually thereafter. 
GFR je treba oceniti pred uvedbo zdravljenja z zdravili, ki vsebujejo metformin, nato pa vsaj enkrat letno.
Further symptoms are reduced body temperature and heartbeat. 
Dodatna simptoma sta znižana telesna temperatura in zmanjšan srčni utrip.
If no adequate strength of Jentadueto is available, individual monocomponents should be used instead of the fixed dose combination. 
Če ni na voljo ustrezna jakost zdravila Jentadueto, je treba namesto fiksne kombinacije uporabiti posamične monokomponente.
Following an oral dose, the apparent terminal elimination half-life is approximately 6.5 hours. 
Po peroralnem odmerku je navidezni končni razpolovni čas izločanja približno 6,5 ure.
What is type 2 diabetes? 
Kaj je sladkorna bolezen tipa 2
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 20 July 2012 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Z ZDRAVILOM Datum prve odobritve: 20. julij 2012 Datum zadnjega podaljšanja: 22. marec 2017
The absolute bioavailability of linagliptin is approximately 30%. 
Absolutna biološka uporabnost linagliptina je približno 30-odstotna.
This can lead to serious medical problems like heart disease, kidney disease, blindness, and amputation. 
Posledica so lahko resne zdravstvene težave, kot so srčna bolezen, ledvična bolezen, slepota in amputacija.
Plasma protein binding is negligible. 
Vezava na beljakovine v plazmi je zanemarljiva.
Patients should be informed of the characteristic symptoms of acute pancreatitis. 
Bolnike je treba poučiti o značilnih simptomih akutnega pankreatitisa.
* PY=patient years ** Test on non-inferiority to demonstrate that the upper bound of the 95% CI for the hazard ratio is less than 1.3 
* BL = bolnik-let ** preskus neinferiornosti, ki pokaže, da je zgornja meja 95-% IZ za razmerje tveganja nižja od 1,3
The mean age for study population was 64 years and included 2030 (34%) patients ≥ 70 years of age. 
Povprečna starost študijske populacije je bila 64 let, vključevala pa je 2030 (34 %) bolnikov, starih ≥ 70 let.
The adverse reactions are listed by system organ class and absolute frequency. 
Neželeni učinki so navedeni po organskih sistemih in absolutni pogostnosti.
Type 2 diabetes is a condition in which your body does not make enough insulin, and the insulin that your body produces does not work as well as it should. 
Sladkorna bolezen tipa 2 je bolezensko stanje, pri katerem telo ne izdeluje dovolj insulina, tisti, kolikor ga telo izdeluje, pa ne deluje tako, kot bi moral.
When starting or using such products in combination with metformin, close monitoring of renal function is necessary. 
Ob uvedbi ali uporabi teh zdravil v kombinaciji z metforminom je potrebno skrbno spremljanje delovanja ledvic.
Metformin is a substrate of both transporters OCT1 and OCT2. 
Metformin je substrat za prenašalca OCT1 in OCT2.
• Any type of acute metabolic acidosis (such as lactic acidosis, diabetic ketoacidosis) 
• vse vrste akutne metabolične acidoze (kot sta laktacidoza, diabetična ketoacidoza)
Stop taking this medicine immediately and contact a doctor or the nearest hospital straight away (see section 2). 
Takoj prenehajte jemati to zdravilo in se nemudoma posvetujte z zdravnikom ali takoj pojdite v najbližjo bolnišnico (glejte poglavje 2).
If necessary, the dose of the anti-hyperglycaemic medicinal product should be adjusted during therapy with the other medicinal product and on its discontinuation. 
Če je potrebno, je treba odmerek antihiperglikemičnega zdravila prilagoditi med zdravljenjem z drugim zdravilom in ob njegovi ukinitvi.
Diabetic skin problems are a common complication of diabetes. 
Diabetične težave s kožo so pogost zaplet sladkorne bolezni.
Component of a multipack, cannot be sold separately. 
Del večkratnega pakiranja, ki ni za posamično prodajo.
If any of the above apply to you, talk to your doctor for further instructions. 
Če kar koli od zgoraj navedenega velja za vas, se za več navodil posvetujte z zdravnikom.
If acidosis of either form occurs, Jentadueto must be stopped immediately and other appropriate corrective measures initiated. 
Če se pojavi katerakoli acidoza, je treba zdravilo Jentadueto nemudoma ukiniti in uvesti druge ustrezne korektivne ukrepe.
• Hypersensitivity to the active substances or to any of the excipients listed in section 6.1. 
• preobčutljivost na učinkovini ali katero koli pomožno snov, navedeno v poglavju 6.1
Metformin must be discontinued at the time of surgery under general, spinal or epidural anesthesia. 
Uporabo metformina je treba v času kirurškega posega pod splošno, spinalno ali epiduralno anestezijo prekiniti.
What Jentadueto is and what it is used for 
Kaj je zdravilo Jentadueto in za kaj ga uporabljamo
Ketoacidosis is a condition in which substances called ‘ketone bodies' accumulate in the blood and which can lead to diabetic pre-coma. 
Ketoacidoza je stanje, pri katerem se snovi, imenovane 'ketonska telesa', kopičijo v krvi, kar lahko povzroči diabetično predkomo.
The safety and efficacy of Jentadueto in children and adolescents aged 0 to 18 years have not been established. 
Varnost in učinkovitost zdravila Jentadueto pri otrocih in mladostnikih od rojstva do 18 let nista dokazani.
Your doctor may ask you to stop Jentadueto. 
Vaš zdravnik vam bo morda naročil, da zdravilo Jentadueto prenehate jemati.
If you have symptoms of acute pancreatitis, like persistent, severe abdominal pain, you should consult your doctor. 
Če imate simptome akutnega pankreatitisa, kot je persistentna, huda bolečina v trebuhu, se posvetujte s svojim zdravnikom.
The observed pharmacokinetic and pharmacodynamic responses were consistent with those found in adult subjects. 
Opaženi farmakokinetični in farmakodinamični odzivi so bili skladni s tistimi, ki so jih opazili pri odraslih preiskovancih.
The name of your tablet is Jentadueto. 
Vaša tableta se imenuje zdravilo Jentadueto.
• Severe renal failure (GFR <30 ml/min). 
• huda ledvična odpoved ( GFR < 30 ml/min)
Use of DPP-4 inhibitors has been associated with a risk of developing acute pancreatitis. 
Uporaba zaviralcev DPP-4 je povezana s tveganjem za nastanek akutnega pankreatitisa.
The use of linagliptin has not been studied in pregnant women. 
Uporabe linagliptina pri nosečnicah niso proučevali.
If needed, dose adjustment of metformin may be considered as OCT inhibitors/inducers may alter the efficacy of metformin. 
Če je potrebno, odmerek metformina lahko prilagodimo, saj lahko zaviralci/induktorji OCT spremenijo učinkovitost metformina.
Sulphonylureas and insulin are known to cause hypoglycaemia. 
Za sulfonilsečnine in insulin je znano, da povzročajo hipoglikemijo.
The European Medicines Agency has waived the obligation to submit the results of the studies with Jentadueto in all subsets of the paediatric population in type 2 diabetes (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij z zdravilom Jentadueto za vse podskupine pediatrične populacije pri sladkorni bolezni tipa 2 (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
Both incretin hormones are involved in the physiological regulation of glucose homeostasis. 
Oba inkretinska hormona sodelujeta pri fiziološkem uravnavanju homeostaze glukoze.
Keep taking Jentadueto until your doctor tells you to stop. 
Zdravilo Jentadueto jemljite, dokler vam vaš zdravnik ne naroči, da ga prenehate jemati.
• Hepatic impairment, acute alcohol intoxication, alcoholism (see section 4.5). 
• jetrna okvara, akutna zastrupitev z alkoholom, alkoholizem (glejte poglavje 4.5)
Remember to take all medicines as directed by your doctor to achieve the best results for your health. 
Vsa zdravila jemljite tako, kot vam bo naročil vaš zdravnik, da bo njihov učinek na vaše zdravje najboljši.
For prevention, it is recommended that Jentadueto be taken during or after meals. 
Da bi jih preprečili, je priporočeno jemanje zdravila Jentadueto med jedjo ali po njej.
The amount of Jentadueto that you will take varies depending on your condition and the doses you currently take of metformin and/or individual tablets of linagliptin and metformin. 
Količina zdravila Jentadueto, ki jo boste jemali, bo lahko različna, kar je odvisno od vašega stanja in odmerkov metformina in/ali posameznih tablet linagliptina in metformina, ki jih trenutno jemljete.
In the event of an overdose, it is reasonable to employ the usual supportive measures, e.g. remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring, and institute clinical measures if required. 
Po zaužitju prevelikega odmerka je smiselno uvesti običajne podporne ukrepe, na primer odstraniti neabsorbirano vsebino iz prebavil, uvesti klinično spremljanje in po potrebi izvesti klinične ukrepe.
Patients and/or care-givers should be informed of the risk of lactic acidosis. 
Bolnike in/ali negovalce je treba opozoriti na tveganje laktacidoze.
Analysis of the results for overweight patients treated with metformin after failure of diet alone showed: 
Analiza izsledkov pri bolnikih s preveliko telesno maso, ki so se zdravili z metforminom po neuspešni dieti, je pokazala:
GFR should be assessed before treatment initiation and regularly thereafter, see section 4.2. 
GFR je treba oceniti pred uvedbo zdravljenja, nato pa v rednih presledkih, glejte poglavje 4.2.
This is to help keep your blood sugar under control. 
Tako bo vaš krvni sladkor urejen.
Along with diet and exercise, this medicine helps to improve the levels and effects of insulin after a meal and lowers the amount of sugar made by your body. 
Ob dieti in telesni aktivnosti to zdravilo izboljša raven in učinek insulina po jedi in zmanjša količino sladkorja, ki nastaja v telesu.
The blood peak is lower than the plasma peak and appears at approximately the same time. 
Največja koncentracija v krvi je manjša od največje koncentracije v plazmi in se pojavi ob približno istem času.
In patients with stable chronic heart failure, Jentadueto may be used with a regular monitoring of cardiac and renal function. 
Pri bolnikih s stabilnim kroničnim srčnim popuščanjem se zdravilo Jentadueto lahko uporablja ob rednem spremljanju delovanja srca in ledvic.
The following statements reflect the pharmacokinetic properties of the individual active substances of Jentadueto. 
Trditve v nadaljevanju temeljijo na farmakokinetičnih lastnostih posamičnih zdravilnih učinkovin v zdravilu Jentadueto.
Both treatments were added to standard of care targeting regional standards for HbA1c and CV risk factors. 
Obe terapiji sta bili dodani standardni terapiji na podlagi regionalnih standardov za vrednosti HbA1c in tveganja za srčno-žilna obolenja.
Thus full efficacy of linagliptin in combination with strong P-gp inducers might not be achieved, particularly if these are administered long-term. 
Torej je mogoče, da polna učinkovitost linagliptina v kombiniranju z močnimi induktorji P-glikoproteina ne bo dosežena, zlasti pri dolgotrajni uporabi.
A limited amount of data suggests that the use of metformin in pregnant women is not associated with an increased risk of congenital malformations. 
Manjše število podatkov o uporabi metformina pri nosečnicah ne kaže na povečano nevarnost kongenitalnih malformacij.
If you experience any of the signs of illness mentioned above, stop taking Jentadueto and call your doctor right away. 
Če se pojavijo, katerikoli od zgoraj omenjenih znakov bolezni, zdravilo Jentadueto prenehajte jemati in takoj pokličite svojega zdravnika.
What Jentadueto is and what it is used for What you need to know before you take Jentadueto How to take Jentadueto 
Kaj je zdravilo Jentadueto in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Jentadueto Kako jemati zdravilo Jentadueto Možni neželeni učinki
The only observed interaction between linagliptin and metformin was a reduction of body weight gain. 
Edina opažena interakcija med linagliptinom in metforminom je bilo zmanjšanje prirasta telesne mase.
The study population included 1211 (17.4%) patients ≥ 75 years of age and 4348 (62.3%) patients with renal impairment. 
Študijska populacija je vključevala 1211 (17,4 %) bolnikov, starih ≥ 75 let, in 4348 (62,3 %) bolnikov z ledvično okvaro.
If the patient plans to become pregnant, or if pregnancy occurs, treatment with Jentadueto should be discontinued and switched to insulin treatment as soon as possible in order to lower the risk of foetal malformations associated with abnormal blood glucose levels. 
Če bolnica načrtuje nosečnost ali zanosi, je treba zdravljenje z zdravilom Jentadueto čim prej ukiniti in preiti na insulin, da bi zmanjšali nevarnost okvar ploda zaradi nenormalnih ravni glukoze v krvi.
The study included 3494 patients treated with linagliptin (5 mg) and 3485 patients treated with placebo. 
V študiji je sodelovalo 3494 bolnikov, ki so se zdravili z linagliptinom (5 mg), in 3485 bolnikov, ki so se zdravili s placebom.
The prospective randomised (UKPDS) study has established the long-term benefit of intensive blood glucose control in type 2 diabetes. 
V prospektivni randomizirani študiji (UKPDS) je bila dokazana dolgoročna korist intenzivnega urejanja ravni glukoze v krvi pri sladkorni bolezni tipa 2.
In case of suspected symptoms, the patient should stop taking metformin and seek immediate medical attention. 
Ob sumu na simptome mora bolnik prenehati z jemanjem metformina in takoj poiskati zdravniško pomoč.
Talk to your doctor for further instruction. 
Za več navodil se posvetujte z zdravnikom.
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/. 
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu.
Incidence Rate per 1000 PY* 
število preiskovancev stopnja pojavnosti na 1000 BL*
Jentadueto with alcohol 
Zdravilo Jentadueto skupaj z alkoholom
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Jentadueto therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman. 
Odločiti se je treba med prenehanjem dojenja in prenehanjem/prekinitvijo zdravljenja z zdravilom Jentadueto, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
You should continue your diet during treatment with Jentadueto and take care that your carbohydrate intake is equally distributed over the day. 
Med zdravljenjem z zdravilom Jentadueto morate nadaljevati z dieto in paziti, da boste vnos ogljikovih hidratov enakomerno porazdelili čez ves dan.
OUTER CARTON AND LABEL - HDPE BOTTLE (17 AND 18 APPLICABLE ONLY FOR CARTON) 
PODATKI NA ZUNANJI IN STIČNI OVOJNINI KARTONSKA ŠKATLA IN NALEPKA - HDPE PLASTENKA (17 IN 18 PRIMERNO SAMO ZA KARTONSKO ŠKATLO)
With metformin there was no change in AUC, however mean peak serum concentration of metformin was decreased by 18% when administered with food. 
AUC metformina se ni spremenila, toda srednja največja koncentracija metformina v serumu se je pri jemanju s hrano zmanjšala za 18 %.
Jentadueto should be taken twice daily with meals to reduce the gastrointestinal adverse reactions associated with metformin. 
Zdravilo Jentadueto je treba jemati dvakrat na dan ob jedi, da bi zmanjšali neželene učinke na prebavila, povezane z metforminom.
The patient should be informed and more frequent blood glucose monitoring performed, especially at the beginning of treatment with such medicinal products. 
Bolnika je treba o tem poučiti in zlasti na začetku zdravljenja s temi zdravili pogosteje spremljati njegovo raven glukoze v krvi.
The effect of Jentadueto on human fertility has not been studied. 
Študij o učinku zdravila Jentadueto na plodnost pri človeku niso izvedli.
Lactic acidosis is a medical emergency and must be treated in a hospital. 
Laktacidoza je urgentno zdravstveno stanje, ki ga je treba zdraviti v bolnišnici.
Linagliptin binds very effectively to DPP-4 in a reversible manner and thus leads to a sustained increase and a prolongation of active incretin levels. 
Linagliptin se zelo učinkovito reverzibilno veže na DPP-4, česar posledica je enakomerno zvišanje ravni aktivnih inkretinov in podaljšanje njenega trajanja.
General Jentadueto should not be used in patients with type 1 diabetes. 
Splošno Zdravila Jentadueto ne smemo uporabljati za zdravljenje bolnikov s sladkorno boleznijo tipa 1.
Older subjects (65 to 80 years, oldest patient was 78 years) had comparable plasma concentrations of linagliptin compared to younger subjects. 
Starejši (65 do 80 let, najstarejši bolnik je imel 78 let) in mlajši preizkušanci so imeli primerljive plazemske koncentracije linagliptina.
Do not use this medicine if the package is damaged or shows signs of tampering. 
Ne uporabljajte tega zdravila, če opazite poškodovano ovojnino ali znake odpiranja.
Long-term treatment with metformin has been associated with a decrease in vitamin B12 absorption which may very rarely result in clinically significant vitamin B12 deficiency (e.g. megaloblastic anaemia). 
Dolgotrajno zdravljenje z metforminom so povezovali z zmanjšano absorpcijo vitamina B12, kar lahko zelo redko privede do klinično pomembnega pomanjkanja tega vitamina (npr. megaloblastne anemije).
After an oral dose, the non-absorbed fraction recovered in faeces was 20-30%. 
Po peroralnem odmerku znaša neabsorbirani delež, ki se pojavi v blatu, od 20 do 30 %.
This medicine can be used alone or with certain other medicines for diabetes like sulphonylureas, empagliflozin, or insulin. 
To zdravilo lahko uporabljate samostojno ali hkrati z nekaterimi drugimi zdravili za sladkorno bolezen, na primer s sulfonilsečninami, empagliflozinom ali insulinom.
Body weight did not differ significantly between the groups. 
Telesna masa se med skupinami ni pomembno razlikovala.
After an oral dose of metformin, Tmax is reached in 2.5 hours. 
Po peroralni uporabi doseže metformin Tmax v 2,5 ure.
Metformin hydrochloride increases the transport capacity of all types of membrane glucose transporters (GLUTs) known to date. 
Metforminijev klorid poveča sposobnost prenosa vseh doslej znanih membranskih prenašalcev glukoze (GLUT).
If you encounter blistering of the skin it may be a sign for a condition called bullous pemphigoid. 
Če se pojavi mehurjavost kože, je to morda lahko znak obolenja, imenovanega bulozni pemfigoid.
You may need more frequent blood glucose and kidney function tests, or your doctor may need to adjust the dosage of Jentadueto. 
Morda boste morali pogosteje opravljati preiskave glukoze v krvi in delovanja ledvic, zdravnik pa bo morda moral prilagoditi odmerek zdravila Jentadueto.
Adverse reactions previously reported with one of the individual active substances may be potential adverse reactions with Jentadueto, even if not observed in clinical trials with this medicinal product. 
Neželeni učinki, o katerih so pred tem poročali pri posameznih učinkovinah, so lahko potencialni neželeni učinki tudi pri zdravilu Jentadueto, četudi niso bili opaženi v kliničnih preskušanjih tega zdravila.
Other medicines and Jentadueto 
Druga zdravila in zdravilo Jentadueto
Immune system disorders Hypersensitivity (e.g. bronchial hyperreactivity) 
Bolezni imunskega sistema preobčutljivost (npr. bronhialna hiperreaktivnost)
Therefore, caution is advised when Jentadueto is used in combination with a sulphonylurea and/or insulin. 
Zato svetujejo previdnost pri uporabi zdravila Jentadueto v kombinaciji s sulfonilsečnino in/ali insulinom.
Diagnostic laboratory findings are decreased blood pH (<7.35), increased plasma lactate levels (>5 mmol/l) and an increased anion gap and lactate/pyruvate ratio. 
Diagnostični laboratorijski izvidi so zmanjšan pH krvi (< 7,35), zvišane ravni laktata v plazmi (> 5 mmol/l) in povečana anionska vrzel ter razmerje laktat/piruvat.
Your doctor may prescribe this medicine together with another oral anti-diabetic medicine or insulin. 
Zdravnik vam lahko to zdravilo predpiše hkrati z drugim antidiabetikom ali insulinom.
Metformin hydrochloride may act via 3 mechanisms: 
Metforminijev klorid lahko deluje na tri načine:
What you need to know before you take Jentadueto Do not take Jentadueto - if you are allergic to linagliptin or metformin or any of the other ingredients of this medicine 
Kaj morate vedeti, preden boste vzeli zdravilo Jentadueto Ne jemljite zdravila Jentadueto - če ste alergični na linagliptin ali metformin ali katero koli sestavino tega zdravila (navedeno v poglavju 6),
Elderly Caution should be exercised when treating patients 80 years and older (see section 4.2). 
Starejši Pri zdravljenju bolnikov, starih 80 let in več, je potrebna previdnost (glejte poglavje 4.2).
83% of patients were taking metformin in combination with insulin in this trial. 
V tej študiji je 83 % bolnikov jemalo metformin v kombinaciji z insulinom.
Evaluation should include serum electrolytes and ketones, blood glucose and, if indicated, blood pH, lactate, pyruvate, and metformin levels. 
Ocena mora zajeti raven elektrolitov in ketonov v serumu, glukoze v krvi in, če je indicirano, pH krvi ter ravni laktata, piruvata in metformina.
No clinically relevant effect of Cmax and Tmax changes is expected; therefore linagliptin may be administered with or without food. 
Klinično pomembnih posledic sprememb vrednosti Cmax in Tmax ni pričakovati, zato lahko bolniki jemljejo linagliptin s hrano ali brez nje.
The most effective method to remove lactate and metformin hydrochloride is haemodialysis. 
Najučinkovitejša metoda odstranjevanja laktata in metforminijevega klorida je hemodializa.
In vitro assessment of interactions 
Ocena medsebojnega delovanja in vitro
• in patients already being treated with the combination of linagliptin and metformin as separate tablets. 
• pri bolnikih, ki se že zdravijo s kombinacijo linagliptina in metformina v ločenih tabletah.
Based on these studies there is no concern for carcinogenicity in humans. 
Podatki študij kažejo, da ni tveganja za karcinogenost pri človeku.
Due to the metformin component, Jentadueto may cause a very rare, but very serious complication called lactic acidosis, particularly if your kidneys are not working properly. 
Zaradi metformina lahko zdravilo Jentadueto povzroči zelo redek, a zelo resen neželeni učinek, imenovan laktacidoza, zlasti če ledvice ne delujejo pravilno.
Results were consistent for patients treated with or without metformin. 
Rezultati so bili enaki pri bolnikih, ki so bili ali niso bili zdravljeni z metforminom.
It is not an inducer of CYP isozymes. 
Ni induktor izocimov CYP.
A dose reduction of the sulphonylurea or insulin may be considered (see section 4.2). 
Presoditi je treba o zmanjšanju odmerka sulfonilsečnine ali insulina (glejte poglavje 4.2).
Therefore, it is considered unlikely that linagliptin affects reproduction at therapeutic exposures in humans. 
Zato ni verjetno, da bi linagliptin pri izpostavljenosti terapevtskim odmerkom vplival na reprodukcijo pri človeku.
Because glibenclamide is primarily metabolised by CYP2C9, these data also support the conclusion that linagliptin is not a CYP2C9 inhibitor. 
Ker glibenklamid primarno presnavlja CYP2C9, ta izsledek potrjuje, da linagliptin ne zavira CYP2C9.